This review assessed the use of aspirin in the primary prevention of cardiovascular disease. Strong support was found for aspirin preventing a first heart attack in apparently healthy individuals. Evidence on strokes or vascular deaths failed to yield conclusive results. Although review methods were poorly reported, the authors' conclusions appear supported by the evidence presented.
Methods of synthesis
How were the studies combined? Stratified analyses were performed by trial to avoid direct comparisons between individuals within trials. The authors describe a non-standard meta-analytical method. They also said that in the analysis they doubled the numbers in the control group for one study as randomisation had taken place on a 2:1 basis. The relative risks (RRs) and 95% confidence intervals (CIs) were presented.
How were differences between studies investigated?
The authors did not state a method for assessing any differences between the studies. They did, however, report on heterogeneity in the results.
Results of the review
Five RCTs (55,580 participants) were included. The results of one study were only used in the combined vascular events outcome.
There was no significant heterogeneity between the studies.
For nonfatal MI there was a statistically-significant risk reduction of 32% associated with aspirin therapy (RR 0.68, 95% CI: 0.59, 0.79).
There was no significant effect of aspirin use on nonfatal stroke (RR 1.06, 95% CI: 0.87, 1.29) or ischaemic stroke (RR 0.97, 95% CI: 0.77, 1.22); there was a suggestion that aspirin use increased the risk of haemorrhagic stroke (RR 1.56, 95% CI: 0.99, 2.46).
There was a statistically-significant reduction in the risk of any important vascular event in the aspirin-treated group (RR 0.85, 95% CI: 0.79, 0.93). For vascular deaths there was no significant reduction in risk (RR 0.98, 95% CI: 0.85, 1.12).
